Recent Key Hires Omeros Corporation has appointed key personnel like David Borges as chief accounting officer and Andreas Grauer as chief medical officer, indicating a focus on strengthening the leadership team and potentially opening doors for partnership and business opportunities.

Innovative Treatment Launch The launch of the narsoplimab treatment report for hematopoietic stem cell transplant-associated thrombotic microangiopathy showcases Omeros as a company at the forefront of innovative medical solutions, creating sales opportunities through cutting-edge therapies.

Significant Grant Funding Receiving a $6.7M grant for testing a cocaine treatment drug candidate demonstrates strong support for Omeros' research endeavors, presenting avenues for collaborations with funders and potential commercialization opportunities.

Asset Sale and Financing Completing a $1B asset sale to Rayner Surgical Group and securing $125M in financing indicate robust financial health, potentially attracting investors, partners, and clients interested in the company's assets and growth prospects.

Market Presence and Revenue Potential With an established revenue range of $10M - 50M, Omeros stands as a significant player in the biotechnology sector, presenting sales opportunities for companies seeking strategic collaborations or acquisitions within a similar revenue bracket.